Although management of hyperglycaemia represents one of the principal treatment goals of diabetes therapy, the high incidence of cardiovascular (CV) complications in diabetes also needs effective management. Therefore, the present study was designed to determine and compare the effect of glitazones on serum sialic acid (SSA), a known risk marker for CV disease, along with fasting plasma glucose (FPG), glycohaemoglobin (HbA1-c) and blood lipids, in overweight, previously only diet-treated patients with type 2 diabetes (n=60). The study was conducted for a period of 12 months. Significant improvement in FPG and HbA1-c were shown by both rosiglitazone (p<0.003 and p<0.001, respectively) and pioglitazone (p<0.005 and p<0.001, respectively), compared with baseline, and pioglitazone showed greater beneficial effects on other parameters monitored, significantly reducing total cholesterol (TC) (p≤0.05). Both the drugs showed a decrease in SSA and no significant differences were observed between the groups. However, the decrease was significant only in the pioglitazone-treated group at month 12 (p≤0.05), compared with baseline. A significant decrease in SSA by pioglitazone indicates its greater cardioprotective effect compared with rosiglitazone.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1479164111428629 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serum metabolomics and 16S rRNA amplicon sequencing reveal the role of puerarin in alleviating bone loss aggravated by antidiabetic agent pioglitazone in type 2 diabetic mice.
J Ethnopharmacol
January 2025
State Key Laboratory of Traditional Chinese Medicine Syndrome, Department of Orthopaedics, The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, PR China; Department of Orthopaedics, The First Affiliated Hospital, Guangzhou University of Chinese Medicine, 16 Jichang Road, Baiyun Area, Guangzhou, PR China. Electronic address:
Ethnopharmacological Relevance: Pioglitazone (PIO) was an anti type 2 diabetes (T2D) agent but caused bone loss and bone marrow fat accumulation. Puerarin (PUE) was a natural component of herbal medicine extracted from Pueraria lobata (Willd.) Ohwi and reduced glycemia and improved bone mass as a supplementary drug.
View Article and Find Full Text PDFChiglitazar ameliorates dehydroepiandrosterone-induced polycystic ovary syndrome in rats.
J Ovarian Res
November 2024
Department of Endocrinology, Chongqing University Three Gorges Hospital, Chongqing, 404000, China.
Background: Polycystic ovary syndrome (PCOS) is an endocrine and metabolic disorder accompanied by ovulatory dysfunction. Insulin resistance (IR) is a key pathogenic mechanism in PCOS, and insulin sensitizers, such as metformin and pioglitazone, can improve PCOS symptoms. Chiglitazar, a pan-peroxisome proliferator-activated receptor (pan-PPAR) agonist, is also an insulin sensitizer; however, its therapeutic effects have not yet been studied in PCOS.
View Article and Find Full Text PDFEvaluation of the Effect of an α-Adrenergic Blocker, a PPAR-γ Receptor Agonist, and a Glycemic Regulator on Chronic Kidney Disease in Diabetic Rats.
Int J Mol Sci
October 2024
Department of Microbiology, Basic Sciences Center, Universidad Autónoma de Aguascalientes, Aguascalientes 20100, Mexico.
Diabetic nephropathy (DN) is a globally widespread complication of (DM). Research indicates that pioglitazone and linagliptin mitigate the risk of DN by reducing inflammation, oxidative stress, and fibrosis. The role of tamsulosin in DN is less studied, but it may contribute to reducing oxidative stress and inflammatory responses.
View Article and Find Full Text PDFGeneration of affinity maps for thiazolidinediones with human serum albumin using affinity microcolumns. II. Effects of advanced glycation end products on multisite drug binding.
J Chromatogr B Analyt Technol Biomed Life Sci
October 2024
Department of Chemistry, University of Nebraska-Lincoln, USA. Electronic address:
Article Synopsis
- The study investigated how two drugs, pioglitazone and rosiglitazone, interact with modified forms of human serum albumin (HSA) to explore multisite protein interactions.
- Strong binding was observed at Sudlow sites I and II, but modifications to HSA decreased the binding affinities of both drugs, particularly with glyoxal (Go) and methylglyoxal (MGo) modifications.
- The research highlights the use of affinity microcolumns to analyze complex drug-protein interactions, which may have implications for understanding how drug efficacy can change in diseases like diabetes.
Serum biochemical evaluation following administration of imidazolyl thiazolidinedione in streptozotocin-induced diabetic rats.
J Mol Histol
December 2024
Department of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
Article Synopsis
- Diabetes is a significant global health issue, with Type 2 Diabetes Mellitus (T2DM) affected by genetic, environmental, and lifestyle factors, making management challenging.
- The study focused on a new antidiabetic agent, PA9, to evaluate its impact on various serum parameters in diabetic rats after treatment.
- Results showed that PA9 effectively lowered cholesterol and triglyceride levels, protected liver and heart functions, and reduced oxidative stress, indicating its potential as a therapeutic option for diabetes management.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!